HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-08-13Clinical Trial Update: Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection [Phase 4]
Phase 4 clinical trial comparing hepatic safety of raltegravir versus efavirenz in HIV patients coinfected with hepatitis C; results complet…
-
CLINICAL_TRIALS trial_result · 2021-08-12Clinical Trial Update: IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children [Phase 4]
Phase 4 trial update on steady-state pharmacokinetics of an HIV treatment in malnourished HIV-infected children; results completed and poste…
-
CLINICAL_TRIALS trial_result · 2021-08-09Clinical Trial Update: Reducing Antiretroviral Treatments [Phase 3]
Phase 3 clinical trial investigating strategies to reduce antiretroviral treatment in HIV-1 infection.
-
CLINICAL_TRIALS trial_result · 2021-08-06Clinical Trial Update: Evaluation of a Tailored Virtual Intervention to Empower Persons Living With HIV for Therapy Self-management [Phase 3]
Phase 3 clinical trial evaluating a tailored virtual intervention to empower people living with HIV for therapy self-management has complete…
-
FDA approval · 2021-07-29FDA Approved: SYMTUZA — Supplemental Application (Janssen Products LP)
FDA approved a supplemental application for SYMTUZA (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) from Janssen Products …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-07-29Clinical Trial Update: Care4Today v2.0 Application for Improving Adherence to HIV Medications [NA]
A completed clinical trial update for the Care4Today v2.0 app aimed at improving adherence to HIV medications; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-07-28Clinical Trial Update: Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study) [Phase 3]
Phase 3 study evaluating switching to dolutegravir/lamivudine after virological suppression in HIV-1 infection.
-
FDA approval · 2021-07-23FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
FDA approves a supplemental application for Prezista (darunavir) submitted by Janssen Products LP.
-
FDA approval · 2021-07-23FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
FDA approved a supplemental application for PREZISTA (darunavir) from Janssen Products LP, updating its labeling to reflect the approved cha…
-
FDA approval · 2021-07-23FDA Approved: PREZCOBIX — Supplemental Application (Janssen Products, LP)
FDA approves a supplemental application for PREZCOBIX (DARUNAVIR ETHANOLATE AND COBICISTAT) from Janssen Products, LP.
-
CLINICAL_TRIALS trial_result · 2021-07-22Clinical Trial Update: The Role of Home Packs of HIV PEPSE in High Risk Individuals [Phase 4]
Phase 4 trial update evaluating home packs of HIV post-exposure prophylaxis in high-risk individuals.
-
CLINICAL_TRIALS trial_result · 2021-07-20Clinical Trial Update: Understanding and Intervening With Heavy Drinking Among Patients With HIV and HCV [NA]
Clinical trial update on interventions for heavy drinking among patients with HIV and HCV, with completed status and results posted.
-
FDA approval · 2021-07-09FDA Approved: TIVICAY — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for Tivicay (dolutegravir) submitted by ViiV Healthcare Company.
-
FDA label_change · 2021-07-09FDA Approved: JULUCA — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for JULUCA (dolutegravir and rilpivirine) submitted by ViiV Healthcare Company to update the labelin…
-
FDA approval · 2021-07-09FDA Approved: TIVICAY PD — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for Tivicay PD (dolutegravir sodium) submitted by ViiV Healthcare Company.
-
CLINICAL_TRIALS trial_result · 2021-07-07Clinical Trial Update: Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir [Phase 4]
Phase 4 trial evaluating the effect on liver fat and metabolic parameters when switching a protease inhibitor or efavirenz to raltegravir in…
-
FDA approval · 2021-07-01FDA Approved: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved the Original Application for a generic fixed-dose combination emtricitabine and tenofovir disoproxil fumarate from Zydus Pharma…
-
FDA approval · 2021-06-28FDA Approved: SYMTUZA — Supplemental Application (Janssen Products LP)
The FDA approved a supplemental application for SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) submitted by Janssen Prod…
-
CLINICAL_TRIALS trial_result · 2021-06-25Clinical Trial Update: Financial Incentives to Increase Pediatric HIV Testing [NA]
A completed clinical trial evaluating financial incentives to increase HIV testing in pediatric populations; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-06-16Clinical Trial Update: A Study of the Safety and Antiretroviral Activity of 3BNC117 [Phase 2]
Phase 2 trial assessing safety and antiretroviral activity of 3BNC117 in HIV-1 infection has completed.
-
FDA approval · 2021-06-14FDA Approved: ETRAVIRINE — Original Application (AvKARE)
The FDA approved AvKARE's original application for etravirine, a NNRTI used in combination with other antiretrovirals to treat HIV-1 infecti…
-
CLINICAL_TRIALS withdrawal · 2021-06-10Clinical Trial Update: Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls. [Phase 4]
A Phase 4 pharmacokinetic trial evaluating single-dose dolutegravir in HIV-seronegative subjects with severe hepatic impairment compared to …
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672) [Phase 2]
Phase 2 trial update for Vicriviroc (SCH 417690) in combination with optimized ART in experienced HIV patients; study completed with results…
-
FDA approval · 2021-06-04FDA Approved: LOPINAVIR AND RITONAVIR — Original Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' original application for a generic lopinavir/ritonavir product for the treatment of HIV-1 infection…
-
FDA approval · 2021-06-04FDA Approved: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approves Lupin Pharmaceuticals' generic fixed-dose combination emtricitabine and tenofovir disoproxil fumarate (emtricitabine/tenofovir …